Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/12/2026 | $16.00 | Buy | B. Riley Securities |
| 1/9/2026 | Overweight | Piper Sandler | |
| 11/22/2022 | $9.00 → $12.00 | Neutral → Overweight | Cantor Fitzgerald |
| 9/7/2022 | $11.00 | Overweight | CapitalOne |
| 8/8/2022 | $14.00 | Buy | Craig Hallum |
4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~ ~ Real-World Evidence Shows Administration of PEDMARK® Approximately Six Hours After Cisplatin Can Be Safe & Easily Integrated into Patient Care and Does Not Compromise Cisplatin's Established Antitumor Activity ~ RESEARCH TRIANGLE PARK, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as
RESEARCH TRIANGLE PARK, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) ("Fennec" or the "Company"), a specialty pharmaceutical company, today announced that on May 11, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of stock option awards ("Stock Options") to purchase an aggregate of 50,000 of the Company's common shares to three new non-executive employees of the Company with a grant date of May 18, 2026 under the Company's 2026 Equity Inducement Plan (the "Inducement Plan"). The Stock Options consist of incentive stock options to purchase an aggregate of 49,141 shares and nonqualified stock options to pur
~ Achieved First Quarter 2026 Total Net Revenues of $15.1 Million, Up 73% Year Over Year ~ ~ Field Sales Expansion Showing Early Signs of Positive Results with Record PEDMARK® Demand in April 2026 ~ ~ Initiated Third Institution-Led Clinical Study Evaluating PEDMARK® in Adolescent and Young Adult (AYA) and Adult Patients with Head and Neck and Testicular Cancers ~ ~ Four Abstracts Evaluating PEDMARK® will be Included in the Upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Program ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a sp
4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
Submission status for FENNEC PHARMACEUTICALS INC's drug PEDMARK (ORIG-1) with active ingredient SODIUM THIOSULFATE has changed to 'Approval' on 09/20/2022. Application Category: NDA, Application Number: 212937, Application Classification: Type 5 - New Formulation or New Manufacturer
B. Riley Securities initiated coverage of Fennec Pharmaceuticals with a rating of Buy and set a new price target of $16.00
Piper Sandler initiated coverage of Fennec Pharmaceuticals with a rating of Overweight
Cantor Fitzgerald upgraded Fennec Pharmaceuticals from Neutral to Overweight and set a new price target of $12.00 from $9.00 previously
8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
10-Q - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
~ Achieved First Quarter 2026 Total Net Revenues of $15.1 Million, Up 73% Year Over Year ~ ~ Field Sales Expansion Showing Early Signs of Positive Results with Record PEDMARK® Demand in April 2026 ~ ~ Initiated Third Institution-Led Clinical Study Evaluating PEDMARK® in Adolescent and Young Adult (AYA) and Adult Patients with Head and Neck and Testicular Cancers ~ ~ Four Abstracts Evaluating PEDMARK® will be Included in the Upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Program ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a sp
RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2026 financial results before the opening of the U.S. financial markets on Thursday, May 14, 2026. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date: Thursday, May 14, 2026Time: 8:30 a.m. Eastern TimeWebcast Link: https://edge.media-server.com/mmc/p/2iptdco4Participant Link: https://register-conf.media-server.com/register/BIaa4b518aeb974d02873eccf8f56d92f3
~ Delivered Record Annual Revenue with Full-Year Net PEDMARK® Product Sales of $44.6 Million, Representing 50% Year-Over-Year Growth, and Q4 2025 Net Product Sales of $13.8 Million, Representing 75% Growth Over Q4 2024 Net Product Sales ~ ~ Executed on 2025 Clinical Data Strategy to Expand Real-World Validation of PEDMARK® Across New Tumor Types and Patient Populations Through Independent, Institution-Led Research ~ ~ Achieved Record Performance with All-Time High Patient Enrollments and Conversion Rates in Q4 2025, Reflecting Strong Field Execution ~ ~ Completed Oversubscribed $42 Million Equity Offerings with Participation from New and Existing Investors ~ ~ Announced Positive Toplin
SC 13G/A - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)
SC 13G - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)
SC 13G - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)
~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~ ~ Assumes Leadership Role at Critical Time to Expand Use of PEDMARK®, the First and Only Approved Treatment to Reduce the Risk of Cisplatin-Induced Ototoxicity ~ RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced the appointment of Mr. Jeff Hackman as its Chief Executive Officer (CEO) and a member of the Board of Directors, effective on or about August 16, 2024. Jeff will guide Fennec's strategic direction for operational success in the expansion of PEDMARK® use in c